FibroBiologics, Inc. - Common Stock (NQ:FBLG)

0.2480 -0.0020 (-0.80%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Price and Volume

Volume	213,763
Open	0.2500
Bid (Size)	0.2401 (800)
Ask (Size)	0.2670 (1,600)
Prev. Close	0.2500
Today's Range	0.2480 - 0.2675
52wk Range	0.2201 - 1.530
Shares Outstanding	38,262,586
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Get insights into the top gainers and losers of Wednesday's after-hours session. ↗

February 18, 2026

Via Chartmill

FibroBiologics’ Chairman & CEO Pete O’Heeron Selected to Present at A4LI’s H-SPAN Summit at Georgetown University

February 10, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

Performance

YTD	+3.4%	+3.4%
1 Month	-23.1%	-23.1%
3 Month	-23.6%	-23.6%
6 Month	-57.9%	-57.9%
1 Year	-78.4%	-78.4%

More News

FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia

February 05, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics to Present at the DealFlow Discovery Conference

January 20, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics CEO Issues Letter to Shareholders

January 07, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference

January 06, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease

January 05, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis

December 31, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

December 16, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

Monday's session: top gainers and losers ↗

December 15, 2025

Via Chartmill

Which stocks are gapping on Monday? ↗

December 15, 2025

Via Chartmill

Monday's pre-market session: top gainers and losers ↗

December 15, 2025

Via Chartmill

FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

December 15, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions

December 10, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Announces Payoff of Outstanding Debt

November 26, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

November 25, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

Which stocks are experiencing notable movement on Monday? ↗

November 24, 2025

Via Chartmill

Top movers in Monday's session ↗

November 24, 2025

Via Chartmill

The market is filled with gapping stocks in Monday's session. ↗

November 24, 2025

Via Chartmill

FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

November 24, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

November 20, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

November 19, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

November 19, 2025

Via Benzinga

FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

November 19, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

November 12, 2025

Via Benzinga

Frequently Asked Questions

Is FibroBiologics, Inc. - Common Stock publicly traded?

Yes, FibroBiologics, Inc. - Common Stock is publicly traded.

What exchange does FibroBiologics, Inc. - Common Stock trade on?

FibroBiologics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for FibroBiologics, Inc. - Common Stock?

The ticker symbol for FibroBiologics, Inc. - Common Stock is FBLG on the Nasdaq Stock Market

What is the current price of FibroBiologics, Inc. - Common Stock?

The current price of FibroBiologics, Inc. - Common Stock is 0.2480

When was FibroBiologics, Inc. - Common Stock last traded?

The last trade of FibroBiologics, Inc. - Common Stock was at 02/20/26 04:00 PM ET

What is the market capitalization of FibroBiologics, Inc. - Common Stock?

The market capitalization of FibroBiologics, Inc. - Common Stock is 9.49M

How many shares of FibroBiologics, Inc. - Common Stock are outstanding?

FibroBiologics, Inc. - Common Stock has 9M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.